menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Dexborneol

    Menu

    Dexborneol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BePharma
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Simcere’s Sanbexin® Approved in China for Acute Ischemic Stroke

                            Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 04, 2024

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BePharma
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sanbexin Sublingual Tablets Receive Breakthrough Therapy Designation from FDA

                            Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.

                            Product Name : Sanbexin

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 05, 2024

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BePharma
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Neurodawn Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

                            Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.

                            Product Name : Sanbexin

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 20, 2024

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Neurodawn Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth